Ten years on: Ongoing challenges in screening for cryptococcal antigenaemia in people with advanced HIV disease in South Africa
Domain:
healthcareRecord type:
paper
Creator:
RhyEmiKylTsh
Publisher:
AOS
Host:
Screening for early asymptomatic cryptococcal antigenaemia is a crucial step in preventing symptomatic cryptococcal meningitis and reducing mortality among people with advanced HIV disease. However, even when early cryptococcal disease is detected, a significant number of people with advanced HIV disease still develop meningitis and die, suggesting barriers to care following a positive serum cryptococcal antigen result. Ten years after the initiation of a national screening programme in South Africa, we discuss progress and implementation challenges and highlight potential solutions identified through a clinical trial to reduce barriers to care for people with early cryptococcal disease. Analysing systems that care for individuals with early cryptococcal disease and creating interventions to optimise available resources are key steps in reducing HIV-associated cryptococcal disease mortality worldwide.
Similar
Replication Data for: Change in plasma cryptococcal antigen titers in Uganda among outpatients with advanced HIV disease from 2017 to 2022 with rollout of national cryptococcal screeningCryptococcal antigenemia in a Nigerian child with advanced HIV disease: a case reportAssessing the impact of Coronavirus (COVID-19) on reflex cryptococcal antigenaemia (CrAg) testing in South AfricaCryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: a cost-effectiveness analysisUsing laboratory data to assess the impact of coronavirus (COVID-19) on reflex cryptococcal antigenaemia (CrAg) testing in South AfricaFigure S1 - Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa